HealthQuill Acquisition
Eli Lilly and Company will acquire gene-editing startup Verve Therapeutics, Inc. for up to $1.3 billion to pocket an early-stage experimental therapy and to develop once-in-a-lifetime treatments for cardiovascular diseases.
Drugs Health Pharma

Eli Lilly to buy Verve for $1.3 billion, expands heart therapy segment

HQ Team June 19, 2025: Eli Lilly and Company will acquire gene-editing startup Verve Therapeutics, Inc. for up to $1.3 billion to pocket an.

Read More
Germany’s BioNTech SE will acquire CureVac N.V., which develops therapies based on messenger RNA, for $1.25 billion in an all-stock deal to expand the former’s mRNA-based cancer immunotherapy candidates.
Drugs Health Pharma

BioNTech SE to acquire CureVac for $1.25 billion in all-stock deal

HQ Team June 12, 2025: Germany’s BioNTech SE will acquire CureVac N.V., which develops therapies based on messenger RNA, for $1.25 billion in.

Read More
Regeneron Pharmaceuticals, Inc. plans to buy most of the assets of the bankrupt genetics and biotechnology company, 23andMe Holding, for $256 million.
Drugs Medical Pharma

Regeneron to buy bankrupt 23andMe Holding assets for $256 million

HQ Team May 20, 2025: Regeneron Pharmaceuticals, Inc. plans to buy most of the assets of the bankrupt genetics and biotechnology company, 23andMe.

Read More
Switzerland’s pharmaceutical company, Novartis AG,  will acquire Regulus Therapeutics for about $1.7 billion to get access to a drug to treat a genetic kidney disease called autosomal dominant polycystic kidney disease.
Drugs Health Pharma

Novartis buys Regulus for $1.7b to grab genetic kidney disease drug

HQ Team April 30, 2025: Switzerland’s pharmaceutical company, Novartis AG,  will acquire Regulus Therapeutics for about $1.7 billion to get access to a.

Read More
Germany’s Merck KGaA, is set to acquire biopharmaceutical company SpringWorks Therapeutics Inc. for $3.9 billion in cash to add rare tumour therapies to its portfolio.
Drugs Medical Pharma

Merck to buy SpringWorks for $3.9b to add rare tumour medicines

HQ Team April 29, 2025: Germany’s Merck KGaA, is set to acquire biopharmaceutical company SpringWorks Therapeutics Inc. for $3.9 billion in cash to.

Read More
Organon has acquired the commercial rights for a biosimilar for intravenous infusion in treating arthritis and Covid-19 from Biogen Inc., for an undisclosed amount.
Drugs Medical Pharma

Organon & Co. buys biosimilar from Biogen for an undisclosed sum

HQ Team April 2, 2025: Organon has acquired the commercial rights for a biosimilar for intravenous infusion in treating arthritis and Covid-19 from.

Read More
Thermo Fisher Scientific to buy Solvemtum’s purification unit for $4.1 billion in cash
Drugs Medical Pharma

Thermo Fisher to buy Solventum’s filtration unit for $4.1 billion in cash

HQ Team March 1, 2025: Thermo Fisher Scientific Inc., will buy Solventum’s purification and filtration business for $4.1 billion in cash to support.

Read More
US-based private equity and advisory investment firm KKR & Co. Inc. will pay CVC Capital Partners $400 million to acquire a majority stake in India’s HealthCare Global Enterprises Ltd. (HCG).
Health Medical Pharma

KKR to acquire majority stake in India’s HCG for $400 million

US-based private equity and advisory investment firm KKR & Co. Inc. will pay CVC Capital Partners $400 million to acquire a majority stake.

Read More
FibroGen Inc., a US-based pharmaceutical company, will sell its China subsidiary to AstraZeneca Plc. for $160 million, allowing the Anglo-Swedish firm to gain access to an anaemia drug in the world’s most populated nation.
Drugs Health Pharma

AstraZeneca Plc buys China unit of FibroGen Inc for $160 million

HQ Team February 21, 2025: FibroGen Inc., a US-based pharmaceutical company, will sell its China subsidiary to AstraZeneca Plc. for $160 million, allowing.

Read More
Bain Capital, a US-based private investment company, will buy the pharmaceutical arm of the Mitsubishi Chemical Group Corp. for $3.3 billion, according to the Massachusetts-based firm.
Drugs Health Medical

Bain Capital to buy Japan’s Mitsubishi Tanabe Pharma for $3.3 billion

Bain Capital, a US-based private investment company, will buy the pharmaceutical arm of the Mitsubishi Chemical Group Corp. for $3.3 billion, according to.

Read More